Inhibrx and Chiesi Enter Agreement for AATD Candidate Worth up to $162.5 Million

Author: Rare Daily Staff

Inhibrx said it has entered into an agreement to grant Chiesi Group an option to exclusively license, develop, and commercialize outside of the United States and Canada INBRX-101, its experimental therapy for alpha-1 antitrypsin deficiency.

The option grant is effective upon a $10 Million equity investment in Inhibrx.

Inhibrx will retain the rights to develop and commercialize INBRX-101 in the United States and Canada, the largest AATD markets.

Alpha-1 antitrypsin deficiency, or AATD, is a rare genetically defined respiratory disease characterized by progressive destruction of lung tissue.

INBRX-101 is an Fc-fusion protein based therapeutic candidate expected to enter clinical development in mid-2019. INBRX-101 is a modified recombinant version of human alpha-1 antitrypsin, or AAT.

“Chiesi has a strong presence in the European respiratory market, and we look forward to initiating our partnership and working with Chiesi to potentially improve the lives of AATD patients,” said Mark Lappe, CEO of Inhibrx.

Photo: Mark Lappe, CEO of Inhibrx